The prognostic impact of Plasminogen Activator Inhibitor Type1 (PAI-I) and Urokinase-type Plasminogen Aktivator (uPA) concentrations in axillary lymph node metastasis in patients with primary breast cancer
Dokumenttyp:
Meeting Abstract
Autor(en):
Artmann, A; Celik, K; Kiechle, M; Schmitt, M; Harbeck, N